150 related articles for article (PubMed ID: 10911933)
1. Mimicking gene defects to treat drug dependence.
Sellers EM; Tyndale RF
Ann N Y Acad Sci; 2000; 909():233-46. PubMed ID: 10911933
[TBL] [Abstract][Full Text] [Related]
2. Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior.
Tyndale RF; Sellers EM
Ther Drug Monit; 2002 Feb; 24(1):163-71. PubMed ID: 11805739
[TBL] [Abstract][Full Text] [Related]
3. [Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese].
Yokoi T; Kamataki T
Nihon Yakurigaku Zasshi; 1998 Jul; 112(1):5-14. PubMed ID: 9755457
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.
Yokoi T; Kamataki T
Pharm Res; 1998 Apr; 15(4):517-24. PubMed ID: 9587945
[TBL] [Abstract][Full Text] [Related]
5. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk.
Tyndale RF; Sellers EM
Drug Metab Dispos; 2001 Apr; 29(4 Pt 2):548-52. PubMed ID: 11259349
[TBL] [Abstract][Full Text] [Related]
6. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes.
Messina ES; Tyndale RF; Sellers EM
J Pharmacol Exp Ther; 1997 Sep; 282(3):1608-14. PubMed ID: 9316878
[TBL] [Abstract][Full Text] [Related]
7. A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption.
Tyndale RF; Pianezza ML; Sellers EM
Nicotine Tob Res; 1999; 1 Suppl 2():S63-7; discussion S69-70. PubMed ID: 11768189
[TBL] [Abstract][Full Text] [Related]
8. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro.
Zhang W; Kilicarslan T; Tyndale RF; Sellers EM
Drug Metab Dispos; 2001 Jun; 29(6):897-902. PubMed ID: 11353760
[TBL] [Abstract][Full Text] [Related]
10. [Genetic polymorphisms of drug metabolizing enzymes].
Fujieda M; Yamazaki H; Kamataki T
Gan To Kagaku Ryoho; 2002 May; 29(5):663-8. PubMed ID: 12040668
[TBL] [Abstract][Full Text] [Related]
11. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking.
Rao Y; Hoffmann E; Zia M; Bodin L; Zeman M; Sellers EM; Tyndale RF
Mol Pharmacol; 2000 Oct; 58(4):747-55. PubMed ID: 10999944
[TBL] [Abstract][Full Text] [Related]
12. Polymorphic drug metabolizing CYP-enzymes--a pathogenic factor in oral lichen planus?
Kragelund C; Hansen C; Reibel J; Nauntofte B; Broesen K; Pedersen AM; Smidt D; Eiberg H; Torpet LA
J Oral Pathol Med; 2009 Jan; 38(1):63-71. PubMed ID: 19192051
[TBL] [Abstract][Full Text] [Related]
13. The impact of CYP2D6 and CYP2C19 polymorphisms on suicidal behavior and substance abuse disorder among patients with schizophrenia: a retrospective study.
Kobylecki CJ; Hansen T; Timm S; Wang A; Jakobsen KD; Sørensen HJ; Rasmussen HB; Werge T
Ther Drug Monit; 2008 Jun; 30(3):265-70. PubMed ID: 18520596
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism.
Oscarson M
Drug Metab Dispos; 2001 Feb; 29(2):91-5. PubMed ID: 11159795
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking.
Sellers EM; Kaplan HL; Tyndale RF
Clin Pharmacol Ther; 2000 Jul; 68(1):35-43. PubMed ID: 10945314
[TBL] [Abstract][Full Text] [Related]
17. The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence.
Howard LA; Sellers EM; Tyndale RF
Pharmacogenomics; 2002 Mar; 3(2):185-99. PubMed ID: 11972441
[TBL] [Abstract][Full Text] [Related]
18. Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity.
Caraco Y; Tateishi T; Guengerich FP; Wood AJ
Drug Metab Dispos; 1996 Jul; 24(7):761-4. PubMed ID: 8818573
[TBL] [Abstract][Full Text] [Related]
19. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence.
Malaiyandi V; Sellers EM; Tyndale RF
Clin Pharmacol Ther; 2005 Mar; 77(3):145-58. PubMed ID: 15735609
[TBL] [Abstract][Full Text] [Related]
20. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans.
Nakajima M; Kwon JT; Tanaka N; Zenta T; Yamamoto Y; Yamamoto H; Yamazaki H; Yamamoto T; Kuroiwa Y; Yokoi T
Clin Pharmacol Ther; 2001 Jan; 69(1):72-8. PubMed ID: 11180041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
